Pyrrolidine derivatives as factor Xa inhibitors

Abstract

The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.

1. A compound of formula (I): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  represents hydrogen, —C 1-6 alkyl, —C 3-6 alkenyl, —C 2-3 alkylNR b R c , —C 2-3 alkylNHCOR b , or phenyl, the phenyl group being optionally substituted by halogen, or R 1  represents a group X—W, wherein X represents —C 1-3 alkylene- and W represents —CN, —CO 2 H, —CONR b R c , —COC 1-6 alkyl, —CO 2 C 1-6 alkyl, or phenyl, the phenyl being optionally substituted by one or more substitutents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH; 
 R 2  and R 3  independently represent hydrogen, —C 1-3 alkyl or —CF 3  with the proviso that one of R 2  and R 3  is —C 1-3 alkyl or —CF 3  and the other is hydrogen; 
 R b  and R c  independently represent hydrogen or —C 1-3 alkyl; 
 A represents 
 
       
         
           
           
               
               
           
         
         Z represents one or two optional substituents independently selected from halogen and OH, 
         alk represents C 2-3 alkylene or C 2-3 alkenylene, 
         B represents one or more optional substituents on ring carbon atoms selected from: 
         (i) one or more substituents selected from —CF 3 , —F, —CO 2 H, —C 1-6 alkyl, —C 1-6 alkylOH, —(C 1-3 alkyl)NR b R c , —(C 0-3 alkyl)CONR b R c  and —(C 0-3 alkyl)CO 2 C 1-3 alkyl, —CONHC 2-3 alkylOH, —CH 2 NHC 2-3 alkylOH, —CH 2 OC 1-3 alkyl and —CH 2 SO 2 C 1-3 alkyl; 
         (ii) a group —Y—R e , 
         Y represents —C 1-3 alkylene-, —CO—, —C 1-3 alkylNH—, —C 1-3 alkylNHCO—, —C 1-3 alkylNHSO 2 —, —CH 2 NHSO 2 CH 2 — or a direct link, 
         R e  represents phenyl, a 5- or 6-membered cycloalkyl or a 5- or 6-membered heterocycle consisting of at least one heteroatom selected from O or S, each of which is optionally substituted by one or more substituents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH; or 
         (iii) a second ring R f  which is fused to the heterocyclic ring, wherein R f  represents phenyl, a 5- or 6-membered cycloalkyl group or a 5- or 6-membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, and the fused bicyclic group is optionally substituted by one or more substituents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH;
 or a pharmaceutically acceptable salt thereof. 
 
       
     
     
       2. A compound as claimed in  claim 1  of the formula (Ia): 
       
         
           
           
               
               
           
         
       
       wherein:
 R 1  represents hydrogen, —C 1-6 alkyl, —C 2-6 alkenyl or a group X—W, wherein X represents —C 1-3 alkylene- and W represents —CN, —CO 2 H, —CONR b R c , —COC 1-6 alkyl, —CO 2 C 1-6 alkyl, or phenyl, the phenyl being optionally substituted by one or more substituents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH; 
 R 2  and R 3  independently represent hydrogen, —C 1-3 alkyl or —CF 3  with the proviso that when one of R 2  and R 3  is —C 1-3 alkyl or —CF 3 , the other is hydrogen; 
 R b  and R c  independently represent hydrogen or —C 1-3 alkyl; 
 A represents 
 
       
         
           
           
               
               
           
         
         Z represents an optional substituent halogen, 
         alk represents C 2-3 alkylene or C 2-3 alkenylene, 
         B represents one or more optional substituents on ring carbon atoms selected from: 
         (i) one or more substituents selected from —CF 3 , —F, —CO 2 H, —C 1-6 alkyl, —C 1-6 alkylOH, —(C 1-3 alkyl)NR b R c , —(C 0-3 alkyl)CONR b R c  and —(C 0-3 alkyl)CO 2 C 1-3 alkyl, —CONHC 2-3 alkylOH, —CH 2 NHC 2-3 alkylOH, —CH 2 OC 1-3 alkyl and —CH 2 SO 2 C 1-3 alkyl; 
         (ii) a group —Y—R e , 
         Y represents —C 1-3 alkylene-, —CO—, —C 1-3 alkylNH—, —C 1-3 alkylNHCO—, —C 1-3 alkylNHSO 2 —, —CH 2 NHSO 2 CH 2 — or a direct link, 
         R e  represents phenyl, a 5- or 6-membered cycloalkyl or a 5- or 6-membered heterocycle consisting of at least one heteroatom selected from O or S, each of which is optionally substituted by one or more substituents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH; or 
         (iii) a second ring R f  which is fused to the heterocyclic ring, wherein R f  represents phenyl, a 5- or 6-membered cycloalkyl group or a 5- or 6-membered aromatic heterocyclic group consisting of at least one heteroatom selected from O, N or S, and the fused bicyclic group is optionally substituted by one or more substituents selected from: —C 1-3 alkyl, —C 1-3 alkoxy, —C 1-3 alkylOH, halogen, —CN, —CF 3 , —NH 2 , —CO 2 H and —OH;
 or a pharmaceutically acceptable salt thereof. 
 
       
     
     
       3. A compound as claimed in  claim 1  wherein R 1  represents hydrogen, —C 1-6 alkyl, —C 3-6 alkenyl, —C 2-3 alkylNR b R c , —C 2-3 alkylNHCOR b , or phenyl, or R 1  represents a group X—W wherein X represents —C 1-3 alkylene- and W represents —CN, —CO 2 H, —CONR b R c , —COC 1-6 alkyl, or —CO 2 C 1-6 alkyl. 
     
     
       4. A compound as claimed in  claim 1  wherein R 2  represents —C 1-3 alkyl or hydrogen. 
     
     
       5. A compound as claimed in  claim 1  wherein R 3  represents —C 1-3 alkyl or hydrogen. 
     
     
       6. A compound as claimed in  claim 1  wherein B represents hydrogen. 
     
     
       7. A compound as claimed in  claim 1  selected from the group consisting of:
 (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; 
 N2-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N2-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinamide; 
 (E)-2-(4-Chlorophenyl)-N-(cyanomethyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; 
 (E)-2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}-N-(2-oxobutyl)ethenesulfonamide; 
 Methyl N-{[(E)-2-(4-chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycinate; 
 N-{[(E)-2-(4-Chlorophenyl)ethenyl]sulfonyl}-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}glycine; 
 (E)-2-(3-Chloro-4-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; and 
 (E)-2-(4-Chloro-3-hydroxyphenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; or a pharmaceutically acceptable salt thereof. 
 
     
     
       8. A pharmaceutical composition comprising a compound according to  claim 1  together with a pharmaceutical carrier and/or excipient. 
     
     
       9. A pharmaceutical composition comprising a compound according to  claim 2  together with a pharmaceutical carrier and/or excipient. 
     
     
       10. A pharmaceutical composition comprising a compound according to  claim 3  together with a pharmaceutical carrier and/or excipient. 
     
     
       11. A pharmaceutical composition comprising a compound according to  claim 4  together with a pharmaceutical carrier and/or excipient. 
     
     
       12. A pharmaceutical composition comprising a compound according to  claim 5  together with a pharmaceutical carrier and/or excipient. 
     
     
       13. A pharmaceutical composition comprising a compound according to  claim 6  together with a pharmaceutical carrier and/or excipient. 
     
     
       14. A pharmaceutical composition comprising a compound according to  claim 7  together with a pharmaceutical carrier and/or excipient.